The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 02, 2016

Filed:

Feb. 16, 2010
Applicants:

Jun Tan, Tampa, FL (US);

Paul Sanberg, Spring Hill, FL (US);

Inventors:

Jun Tan, Tampa, FL (US);

Paul Sanberg, Spring Hill, FL (US);

Assignee:

University of South Florida, Tampa, FL (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/12 (2015.01); A61K 35/16 (2015.01); A61K 35/44 (2015.01);
U.S. Cl.
CPC ...
A61K 35/44 (2013.01); A61K 35/16 (2013.01); A61K 2035/122 (2013.01);
Abstract

Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, Aβ phagocytic activity was increased and soluble and insoluble Aβ protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of Aβpeptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.


Find Patent Forward Citations

Loading…